An operating system for autoimmune clinical trials in community rheumatology, gastroenterology, dermatology, and federally qualified health centers.
Most people living with lupus, Crohn's, rheumatoid arthritis or hidradenitis suppurativa are treated in a community practice near their home and are never told a study exists. Enrollment stalls, protocols amend, and the evidence base ends up describing a population that doesn't look like the country.
Dermatology makes the point sharpest. Psoriasis, atopic dermatitis and hidradenitis suppurativa are managed almost entirely in community practice, and hidradenitis suppurativa most of all: severely under-enrolled, and concentrated in the community and safety-net settings that academic trial sites were never built to reach.
Amyneion inverts that. Rather than moving patients to trial sites, we move trial capability to the practices that already hold the relationship, the chart, and the infusion chair.
Before a protocol is locked, we can tell you how many eligible patients sit inside the network, where they are, and how that cohort fills over time, then run the sites that enroll them.
See the engine runYou keep your panel, your protocols and your infusion suite. We bring the studies, the regulatory scaffolding, coordinator capacity, and the navigator who carries the logistics your staff can't absorb.
See the navigatorRunning enrollment across community autoimmune care produces something no sponsor can buy: consented, longitudinally followed, phenotyped patients who have already said yes to research and live within driving distance of an activated site.
Each study makes the next one faster to fill. The recruitment-ready autoimmune registry becomes the asset the rest of the industry doesn't have.
In the in-practice deployment, eligibility inference runs on infrastructure inside the practice. Protected health information is never pooled into a central lake to make a prediction, and a practice can see exactly what was read and why a patient surfaced.